March 8, 2021 – Abbott (Abbott Park, IL) announced the U.S. launch of NeuroSphere Virtual Clinic, a technology that allows patients to communicate with physicians, ensure proper settings and functionality, and receive new treatment settings remotely as needed.
Approved by the U.S. Food and Drug Administration (FDA), the NeuroSphere Virtual Clinic has the potential to increase access to optimal treatment for patients suffering from chronic pain or movement disorders who don’t live close to a care provider, have difficulty accessing care, or are unable to go to the doctor because of circumstances like COVID-19, the company says.
Abbott’s NeuroSphere Virtual Clinic connects patients and doctors via secure in-app video chat and an integrated remote programming feature, now available within the Abbott patient controller app.
NeuroSphere Virtual Clinic enables clinicians to prescribe new treatment settings remotely to the patient’s neurostimulation device using the clinician programmer app and a new, simple and secure remote care connection.
The NeuroSphere Virtual Clinic is compatible with Abbott’s suite of neuromodulation technologies, including Infinity DBS System for patients with Parkinson’s disease and tremors of the upper extremities in adults with essential tremors; Proclaim XR SCS System for patients living with chronic pain of the trunk and/or limbs; and Proclaim DRG Neurostimulation System for patients with chronic pain in the lower limbs caused by complex regional pain syndrome or causalgia.